

CLAIM AMENDMENTS

IN THE CLAIMS:

This listing of the claims will replace all prior versions, and listing, of claims in the application or previous response to office action:

1-32. (Cancelled)

33. (Withdrawn) An injectable composition comprising:
a biocompatible matrix;
radiopaque particles mixed within said biocompatible matrix, said radiopaque particles size between about 120 μ and 2200 μ ; and
a contrast agent.

34. (Withdrawn) The injectable composition of claim 33, wherein said biocompatible matrix and said radiopaque particles form a slurry.

35. (Withdrawn) The injectable composition of claim 33, wherein the mixture of said biocompatible matrix and said radiopaque particles forms a hard tissue implant material.

36. (Withdrawn) The injectable composition of claim 33, wherein said radiopaque particles have a particles size between about 350 μ and 2200 μ .

37. (Withdrawn) The injectable composition of claim 36, further comprising radiopaque particles for contrast having a particles size between about 120 μ and 350 μ .

38. (Withdrawn) The injectable composition of claim 33, wherein said radiopaque particles have a particles size between about 450 μ and 1600 μ .

39. (Withdrawn) The injectable composition of claim 38, wherein said radiopaque particles have a particles size between about 570 μ and 1150 μ .

40. (Previously Presented) An injectable hard tissue implant composition comprising:
a settable hardenable, flowable matrix comprising polymethylmethacrylate;
radiopaque tracer particles in said flowable matrix, said radiopaque tracer particles
comprising at least particles having a size between about 350 μ and 2200 μ and present in an
amount so as to be individually visible during implantation; and
radiopaque contrast particles comprising at least particles having a particle size between
about 120 μ and 350 μ ;
wherein said contrast particles enhance the visibility of said matrix, and
wherein said radiopaque tracer particles visibly indicate flow of said matrix during
implantation.

41. (Previously Presented) The injectable composition of claim 40, wherein said
radiopaque tracer particles comprise at least particles having a size between about 570 μ and
2200 μ .

42. (Previously Presented) The injectable composition of claim 40, wherein said
radiopaque tracer particles comprise at least particles having a size between about 450 μ and
1600 μ .

43. (Previously Presented) The injectable composition of claim 40, wherein said
radiopaque tracer particles comprise at least particles having a size between about 570 μ and
1150 μ .

44. (Currently Amended) The injectable composition of claim 40, wherein said
radiopaque tracer particles ~~for contrast~~ particles comprise at least particles having a size between
about 120 μ and ~~350 μ~~ 250 μ .

45. (Cancelled)

46. (Withdrawn) The injectable composition of claim 36, further comprising:
radiopaque particles for contrast having a particle size up to about 350 μ .

47. (Withdrawn) An injectable composition comprising:
a hard tissue implant biocompatible matrix; and
radiopaque particles mixed within said biocompatible matrix, said radiopaque particles
having a particle size of about 120 μ to about 2200 μ .

48. (Withdrawn) The injectable composition of claim 47, wherein said biocompatible
matrix and said radiopaque particles form a slurry.

49. (Withdrawn) The injectable composition of claim 47, wherein said radiopaque
particles have a particle size between about 350 μ and 2200 μ .

50. (Withdrawn) The injectable composition of claim 47, wherein said radiopaque
particles have a particle size between about 450 μ and 1600 μ .

51. (Withdrawn) The injectable composition of claim 50, wherein said radiopaque
particles have a particle size between about 570 μ and 1150 μ .

52. (Withdrawn) The injectable composition of claim 49, further comprising:
radiopaque particles for contrast having a particle size between 120 μ and 350 μ .

53. (Withdrawn) The injectable composition of claim 49, further comprising:
radiopaque particles for contrast having a particle size up to about 350 μ .

54. (Cancelled)

55. (Previously presented) The injectable composition of claim 40, wherein the
radiopaque tracer particles is selected from the group consisting of barium sulfate, tungsten,

tantalum, zirconium, platinum, gold, silver, stainless steel, titanium, alloys thereof, combinations thereof, and equivalent materials used as radiographic agents in hard tissue implant materials that can be formed as particles.

56. (Previously presented) The injectable composition of claim 40, wherein the radiopaque contrast particles is selected from the group consisting of barium sulfate, bismuth subcarbonate, bismuth sulfate, powdered tungsten, powdered tantalum, zirconium, combinations thereof, and equivalent materials for use as radiographic agents in hard tissue implant materials that can be formed as particles.

57. (Cancelled)

58. (Previously presented) The injectable composition of claim 40, wherein the matrix and radiopaque tracer particles comprise a slurry.

59. (Previously presented) The injectable composition of claim 58, wherein the slurry comprises an injectable composition for hard tissue implantation.

60. (Previously Presented) The injectable composition of claim 40, wherein the radiopaque tracer particles comprises about 1% of the total weight of the composition.

61. (Previously Presented) ~~The injectable composition of claim 60,~~ An injectable hard tissue implant composition comprising:
a settable hardenable, flowable matrix comprising polymethylmethacrylate;
radiopaque tracer particles in said flowable matrix, said radiopaque tracer particles comprising at least particles having a size between about 350 μ and 2200 μ and present in an amount so as to be individually visible during implantation; and
radiopaque contrast particles comprising at least particles having a particle size between about 120 μ and 350 μ ;

wherein said contrast particles enhance the visibility of said matrix, and wherein said radiopaque tracer particles visibly indicate flow of said matrix during implantation, and wherein the radiopaque tracer particles comprise about 1% of the total weight of the composition, and wherein the radiopaque tracer particles comprises a mixture of barium sulphate and tungsten particles.

62. (Currently Amended) An injectable hard tissue implant composition comprising: a settably hardenable, flowable matrix comprising at least polymethylmethacrylate; and radiopaque tracer particles,

wherein the size of the radiopaque tracer particles comprises at least particles having a size between about 350 μ and 2200 μ and wherein the amount of radiopaque tracer particles present is such that radiopaque tracer particles are individually visible under fluoroscopy during implantation to visually indicate flow of the injectable composition during implantation; and radiopaque contrast particles consisting of particles having a particle size between about 120 μ and 350 μ wherein the contrast particles enhance the visibility of said matrix..

63. (Cancelled)

64. (Cancelled)

65. (Previously presented) The injectable composition of claim 62, wherein the radiopaque tracer particles is selected from the group consisting of barium sulfate, tungsten, tantalum, zirconium, platinum, gold, silver, stainless steel, titanium, alloys thereof, combinations thereof, and equivalent materials used as radiographic agents in hard tissue implant materials that can be formed as particles.

66. (Previously presented) The injectable composition of claim 63, wherein the radiopaque contrast particles contrast particles is selected from the group consisting of barium sulfate, bismuth subcarbonate, bismuth sulfate, powdered tungsten, powdered tantalum,

zirconium, combinations thereof, and equivalent materials for use as radiographic agents in hard tissue implant materials that can be formed as particles.

67. (Previously Presented) The injectable composition of claim 62, wherein the amount of radiopaque tracer particles comprises about 1% of the total weight of the composition.

68. (Previously Presented) The injectable composition of claim 62, wherein the radiopaque tracer particles comprise at least particles sized between about 570 μ and 2200 μ .

69. (Previously Presented) The injectable composition of claim 62, wherein the radiopaque tracer particles comprise at least particles sized between about 450 μ and 1600 μ .

70. (Previously Presented) The injectable composition of claim 40, wherein the radiopaque tracer particles comprise at least particles sized between about 570 μ and 1150 μ .

71. (Cancelled)

72. (Previously Presented) The injectable composition of claim 62, wherein the amount of radiopaque tracer particles comprises about 10% of the total weight of the composition.

73. (Previously Presented) The injectable composition of Claim 62 wherein the radiopaque tracer particles comprise barium sulfate.

74. (Currently Amended) An enhanced visibility composition for implantation into tissue comprising:

| a hard tissue implant material including a settable hardenable, flowable matrix comprising polymethylmethacrylate;

radiopaque tracer particles in said flowable matrix, said radiopaque tracer particles comprising at least particles having a size between about 350 μ and 2200 μ and present in an amount so as to be individually visible during implantation; and

radiopaque contrast particles comprising at least particles having a particle size between about 120 μ and 350 μ ;

wherein said contrast particles enhance the visibility of said matrix; and

wherein said radiopaque tracer particles visibly indicate flow of said matrix during implantation.

75. (Cancelled)